Cancer research results excite scientists and investors
Article Abstract:
Eloxatin, a chemotherapy drug manufactured by Sanofi-Synthelabo SA, is effective as a first line treatment to shrink tumors, as a last-resort treatment when other chemotherapy drugs have failed and as preventive medicine administered after surgery. The approval of the drug by the Food and Drug Administration (FDA) has excited the physicians and scientists in Malvern who managed clinical development of the drug.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Medco settles with U.S., 20 states
Article Abstract:
Medco Health Solutions Inc., the nation's largest pharmacy-benefits manager, has agreed to pay $29.3 million to settle allegations by the attorney general in 20 states in 2004. Medco, which manages the prescription-drug benefits for 62 million Americans, reported that it reached a separate virtually identical agreement with the Justice Department on business practices.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Adolor seeks approval of first drug
Article Abstract:
Adolor Corp., a small Exton pharmaceutical company in pursuit of its first product sought U.S. approval of a drug to speed gastrointestinal recovery after surgery. As the medicine, called Entereg addresses a medical condition for which there is no approved treatment, and Adolor has asked the Food and Drug Administration to give the new drug application priority review.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Commerce is branching out. PSDS investors still on hold with U.S. suit. American Business reports $5 million loss
- Abstracts: Wyeth beats quarterly forecast despite 41% drop. Drug could ease patients' discomfort - and investors'
- Abstracts: Phila. White Pages could turn yellow with age. Year 2000 bug takes a bite of SCT. RCN's 4th-qtr. Losses bigger than expected
- Abstracts: HomeLife Furniture Corp. will not resume operations. Steel firm files for Chapter 11 shelter. Excite@Home users may lose Internet link
- Abstracts: A flag of convenience and quality on the seas. InterDigital soars after U.N. report. Chamber's new task: Bringing home jobs